Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.

Conclusions: There does not appear to be a relationship between adalimumab exposure and risk of adverse events in IBD patients. PMID: 31144993 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research